Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CSL Limited (CSL.AX)
AUD122.96
+1.62 (+1.34%)
AU ASX Healthcare Biotechnology
Address
45 Poplar Road 3052
Melbourne, VIC, AU
Melbourne, VIC, AU
CEO
Gordon Naylor DipCompSc
Website
csl.com.au
IPO
1994-06-01
ISIN AU000000CSL8
Also trades on
Australian Securities Exchange · CSL.AX (AUD)
Other OTC · CMXHF (USD)
Other OTC · CSLLY (USD)
Description
CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD122.96
+1.62 (+1.34%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.09
Float Shares
481.82M
Free Float %
100.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.00% | -3.06% | -22.32% | -34.17% | -48.14% | -44.04% | -60.89% | -68.66% | -66.71% | -17.01% | +11,586.65% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
122.96
DCF (Unlevered)
304.75
+147.8%
DCF (Levered)
575.05
+367.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
58% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 8 | 0 |
| Hold | 8 | +3 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.59
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+5.0% ★ Q4'25: +0.9% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+13.4% Q4'25: -79.5% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+20.3% ★ Q4'25: +12.1% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+26.7% ★ Q4'25: +31.3% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+12.1% ★ Q4'25: +24.9% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+0.2% ★ Q4'25: +0.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×2.24× Q4'25: 1.00× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2000 actual |
Jun 2001 actual |
Jun 2002 actual |
Jun 2003 actual |
Jun 2004 actual |
Jun 2005 actual |
Jun 2006 actual |
Jun 2007 actual |
Jun 2008 actual |
Jun 2009 actual |
Jun 2010 actual |
Jun 2011 actual |
Jun 2012 actual |
Jun 2013 actual |
Jun 2014 actual |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 16 Rev. Ana. 11 EPS Ana. |
Jun 2027 16 Rev. Ana. 11 EPS Ana. |
Jun 2028 15 Rev. Ana. 8 EPS Ana. |
Jun 2029 10 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 275.87M (-100.0%)
|
433.49M
est: 428.94M (+1.1%)
|
752.40M
est: 656.95M (+14.5%)
|
877.98M
est: 862.81M (+1.8%)
|
1.16B
est: 1.17B (-1.2%)
|
2.10B
est: 2.14B (-2.1%)
|
2.11B
est: 2.19B (-3.7%)
|
2.69B
est: 2.54B (+5.9%)
|
3.40B
est: 3.24B (+4.9%)
|
3.73B
est: 3.96B (-5.9%)
|
3.79B
est: 4.15B (-8.8%)
|
4.48B
est: 4.43B (+0.9%)
|
4.54B
est: 4.87B (-6.8%)
|
4.95B
est: 5.15B (-3.9%)
|
5.01B
est: 5.50B (-8.9%)
|
5.46B
est: 5.66B (-3.6%)
|
6.06B
est: 6.20B (-2.2%)
|
7.02B
est: 6.82B (+2.9%)
|
7.46B
est: 7.71B (-3.2%)
|
8.32B
est: 8.44B (-1.4%)
|
9.41B
est: 9.31B (+1.1%)
|
10.33B
est: 10.12B (+2.1%)
|
10.49B
est: 10.62B (-1.2%)
|
13.17B
est: 13.20B (-0.2%)
|
14.69B
est: 14.66B (+0.2%)
|
15.43B
est: 15.60B (-1.1%)
|
14.10B
13.59B – 14.31B
-9.6% YoY
|
14.37B
13.72B – 15.04B
+1.9% YoY
|
14.94B
14.33B – 15.40B
+4.0% YoY
|
16.05B
15.40B – 16.55B
+7.5% YoY
|
| EBITDA |
68.23M
est: 46.97M (+45.3%)
|
56.35M
est: 78.21M (-27.9%)
|
170.62M
est: 62.68M (+172.2%)
|
172.33M
est: 86.07M (+100.2%)
|
285.51M
est: 53.31M (+435.6%)
|
651.39M
est: 293.87M (+121.7%)
|
243.43M
est: 462.79M (-47.4%)
|
807.31M
est: 110.03M (+633.7%)
|
1.09B
est: 728.79M (+50.1%)
|
1.29B
est: 986.11M (+30.7%)
|
1.32B
est: 1.01B (+31.1%)
|
1.47B
est: 1.28B (+15.2%)
|
1.46B
est: 1.29B (+13.2%)
|
1.72B
est: 1.28B (+33.7%)
|
1.85B
est: 1.52B (+21.7%)
|
1.95B
est: 1.65B (+18.7%)
|
1.85B
est: 1.77B (+4.2%)
|
1.94B
est: 1.66B (+17.2%)
|
1.98B
est: 1.83B (+8.1%)
|
2.02B
est: 2.40B (-15.7%)
|
3.14B
est: 2.37B (+32.7%)
|
3.63B
est: 3.11B (+16.9%)
|
3.46B
est: 3.52B (-1.6%)
|
3.90B
est: 3.71B (+5.2%)
|
4.73B
est: 3.88B (+22.1%)
|
5.13B
est: 5.03B (+2.0%)
|
4.60B
4.44B – 4.67B
-8.5% YoY
|
4.69B
4.48B – 4.91B
+1.9% YoY
|
4.88B
4.68B – 5.03B
+4.0% YoY
|
5.24B
5.03B – 5.41B
+7.5% YoY
|
| EBIT |
—
est: 44.88M (-100.0%)
|
69.01M
est: 78.99M (-12.6%)
|
106.92M
est: 109.92M (-2.7%)
|
91.61M
est: 132.72M (-31.0%)
|
194.62M
est: 107.30M (+81.4%)
|
521.23M
est: 354.40M (+47.1%)
|
157.30M
est: 526.95M (-70.1%)
|
694.87M
est: 180.80M (+284.3%)
|
958.49M
est: 819.11M (+17.0%)
|
1.16B
est: 1.09B (+5.5%)
|
1.19B
est: 1.10B (+7.7%)
|
1.30B
est: 1.31B (-1.3%)
|
1.29B
est: 1.32B (-2.8%)
|
1.52B
est: 1.37B (+10.7%)
|
1.66B
est: 1.62B (+2.0%)
|
1.77B
est: 1.76B (+0.8%)
|
1.63B
est: 1.90B (-14.4%)
|
1.78B
est: 1.78B (-0.2%)
|
2.39B
est: 2.01B (+18.9%)
|
2.52B
est: 2.62B (-3.8%)
|
2.72B
est: 2.72B (+0.0%)
|
3.13B
est: 2.96B (+5.8%)
|
2.92B
est: 3.36B (-12.9%)
|
3.07B
est: 3.54B (-13.2%)
|
3.80B
est: 3.70B (+2.6%)
|
4.12B
est: 4.05B (+1.7%)
|
3.78B
3.64B – 3.84B
-6.7% YoY
|
3.85B
3.68B – 4.03B
+1.9% YoY
|
4.00B
3.84B – 4.13B
+4.0% YoY
|
4.30B
4.13B – 4.44B
+7.5% YoY
|
| Net Income |
32.48M
est: 31.00M (+4.8%)
|
39.93M
est: 53.02M (-24.7%)
|
69.70M
est: 63.59M (+9.6%)
|
47.45M
est: 86.61M (-45.2%)
|
153.55M
est: 55.62M (+176.1%)
|
416.72M
est: 279.54M (+49.1%)
|
87.09M
est: 421.27M (-79.3%)
|
457.42M
est: 100.10M (+357.0%)
|
671.45M
est: 539.24M (+24.5%)
|
924.83M
est: 767.07M (+20.6%)
|
894.83M
est: 882.63M (+1.4%)
|
1.01B
est: 989.31M (+1.6%)
|
1.01B
est: 1.03B (-2.2%)
|
1.22B
est: 1.07B (+13.5%)
|
1.31B
est: 1.30B (+0.2%)
|
1.38B
est: 1.39B (-0.6%)
|
1.24B
est: 1.48B (-15.9%)
|
1.34B
est: 1.37B (-2.6%)
|
1.27B
est: 1.52B (-16.2%)
|
1.92B
est: 1.90B (+0.9%)
|
2.17B
est: 2.09B (+4.2%)
|
2.39B
est: 2.29B (+4.2%)
|
2.25B
est: 2.60B (-13.2%)
|
2.19B
est: 2.19B (+0.0%)
|
2.64B
est: 1.76B (+50.0%)
|
3.00B
est: 3.06B (-1.9%)
|
2.70B
2.57B – 2.84B
-11.6% YoY
|
2.82B
2.58B – 3.06B
+4.3% YoY
|
3.05B
2.68B – 3.41B
+8.1% YoY
|
3.35B
3.17B – 3.48B
+9.7% YoY
|
| SGA |
—
est: 46.93M (-100.0%)
|
80.75M
est: 93.60M (-13.7%)
|
111.74M
est: 107.65M (+3.8%)
|
137.66M
est: 138.73M (-0.8%)
|
193.99M
est: 161.28M (+20.3%)
|
386.52M
est: 353.32M (+9.4%)
|
615.59M
est: 390.73M (+57.5%)
|
479.91M
est: 707.43M (-32.2%)
|
619.73M
est: 565.73M (+9.5%)
|
723.45M
est: 707.94M (+2.2%)
|
618.50M
est: 690.53M (-10.4%)
|
699.99M
est: 683.77M (+2.4%)
|
735.92M
est: 709.05M (+3.8%)
|
796.20M
est: 784.03M (+1.6%)
|
796.60M
est: 853.73M (-6.7%)
|
785.80M
est: 845.41M (-7.1%)
|
1.03B
est: 815.18M (+26.3%)
|
1.18B
est: 1.12B (+5.7%)
|
1.17B
est: 1.34B (-13.2%)
|
1.33B
est: 1.43B (-7.3%)
|
1.59B
est: 1.57B (+1.3%)
|
1.71B
est: 1.73B (-1.2%)
|
1.65B
est: 1.96B (-16.0%)
|
2.54B
est: 2.07B (+22.8%)
|
2.43B
est: 2.16B (+12.4%)
|
2.62B
est: 2.62B (-0.2%)
|
2.40B
2.31B – 2.43B
-8.5% YoY
|
2.44B
2.33B – 2.56B
+1.9% YoY
|
2.54B
2.44B – 2.62B
+4.0% YoY
|
2.73B
2.62B – 2.82B
+7.5% YoY
|
| EPS |
0.08
est: 0.07 (+10.3%)
|
0.09
est: 0.09 (+2.6%)
|
0.15
est: 0.14 (+7.5%)
|
0.10
est: 0.09 (+4.7%)
|
0.29
est: 0.14 (+106.0%)
|
0.71
est: 0.40 (+77.5%)
|
0.16
est: 0.50 (-68.3%)
|
0.84
est: 0.76 (+10.1%)
|
1.22
est: 1.15 (+5.7%)
|
1.55
est: 1.44 (+7.9%)
|
1.58
est: 1.72 (-8.4%)
|
1.86
est: 1.87 (-0.3%)
|
1.94
est: 2.02 (-3.8%)
|
2.44
est: 2.52 (-3.2%)
|
2.70
est: 2.80 (-3.6%)
|
2.92
est: 2.94 (-0.8%)
|
2.69
est: 2.75 (-2.0%)
|
2.94
est: 2.97 (-1.1%)
|
2.81
est: 3.77 (-25.5%)
|
4.24
est: 4.21 (+0.7%)
|
4.63
est: 4.67 (-0.9%)
|
5.26
est: 5.12 (+2.7%)
|
6.63
est: 4.87 (+36.1%)
|
4.55
est: 5.17 (-12.0%)
|
5.47
est: 6.02 (-9.1%)
|
6.20
est: 6.43 (-3.6%)
|
5.76
5.28 – 5.85
-10.5% YoY
|
5.97
5.32 – 6.29
+3.7% YoY
|
6.36
5.52 – 7.02
+6.5% YoY
|
6.88
6.52 – 7.16
+8.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-25 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-05 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-04 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-01 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-15 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
8.96B
OE per share TTM
18.43
Owner's Yield
19.18%
Maintenance CapEx ratio
59.27%
Maint CapEx / Avg PPE
78.1%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
2
Total invested
635.3K
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q3
Investors holding
2
+0 vs prev Q
New positions
0
Closed positions
0
Increased
0
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BOSTON COMMON ASSET MANAGEMENT, LLC | — -4.7K (-100.0%) | — -614.2K (-100.0%) | 0.00% -0.001 pp | 0.00% -0.017 pp | AUD— | 12 qtrs SOLD |
| 2 | STRATEGIC INVESTMENT SOLUTIONS, INC. /IL | — -161.0 (-100.0%) | — -21.1K (-100.0%) | 0.00% +0.000 pp | 0.00% -0.006 pp | AUD— | 7 qtrs SOLD |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
125.9K
Shares Outstanding
478.91M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ken Lim | Chief Financial Officer | 3M | male |
| Gordon Naylor DipCompSc | CEO, MD & Director | 3M | male |
| Andy Schmeltz | Chief Commercial Officer | 2M | male |
| William Mezzanotte | Chief Medical Officer, Executive Vice President and Head of Research & Development | 2M | — |
| Gregory Boss | Executive VP of Legal & Group General Counsel | 2M | male |
| Roanne Parry | Chief Human Resources Officer | — | female |
| Stephen Marlow | Executive VP & GM of CSL Plasma | — | male |
| Mark Dehring | Head of Investor Relations | — | male |
| Deirdre BeVard | Senior Vice President of Research & Development Strategic Operations | — | female |
| Amy Van Buren | Chief People Officer | — | female |
| Mark Hill | Chief Digital Information Officer & Executive Vice President | — | male |
| Mary Oates | Executive VP & COO | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CSL.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
